Connection

Jean-Charles Soria to Patient Selection

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Patient Selection.
Jean-Charles Soria
Connection Strength
0.590
Patient Selection
  1. Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? Eur J Cancer. 2020 09; 137:235-239.
    View in: PubMed
    Score: 0.297
  2. Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discov. 2021 06; 11(6):1336-1344.
    View in: PubMed
    Score: 0.078
  3. Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. Eur J Cancer. 2018 07; 98:17-22.
    View in: PubMed
    Score: 0.064
  4. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
    View in: PubMed
    Score: 0.061
  5. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
    View in: PubMed
    Score: 0.061
  6. QTc monitoring during a phase I study: experience with SR271425. Am J Clin Oncol. 2007 Apr; 30(2):106-12.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.